Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer

Journal of Cancer Research and Clinical Oncology
Holm EggemannAtanas Ignatov

Abstract

Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated. MBC was characterized by older age, advanced tumor stage, and higher rate of lymph node metastases, in comparison with FBC. Matching analysis was performed using six prognostic criteria: patient age, tumor stage, tumor grade, lymph node status, human epidermal growth factor receptor (HER2) status, and administration of chemotherapy. The female and male patients were matched 2:1. In this analysis, 316 women and 158 men treated with TAM, and 60 women and 30 men treated with AI, were included. The overall survival (OS) was estimated by the Kaplan-Meier method and was compared between FBC and MBC. TAM-treated FBC and MBC patients had similar 5-year OS, 85.1 and 89.2%, respectively (p = 0.972). Notably, FBC patients treated with AI had significantly greater 5-year OS (...Continue Reading

References

Feb 1, 1992·British Journal of Cancer·G Ribeiro, R Swindell
Feb 22, 2003·Current Treatment Options in Oncology·Matthew D Volm
Mar 6, 2004·Breast Cancer Research and Treatment·William F AndersonSusan S Devesa
Dec 12, 2012·Breast Cancer Research and Treatment·Holm EggemannSerban-Dan Costa
Jul 19, 2015·Endocrine-related Cancer·Holm EggemannAtanas Ignatov

❮ Previous
Next ❯

Citations

Jan 19, 2019·British Journal of Cancer·Holm EggemannAtanas Ignatov
Mar 7, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Sok Kuan WongKok-Yong Chin
Feb 15, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J HassettSharon H Giordano
May 6, 2020·British Journal of Cancer·Holm EggemannAtanas Ignatov
Oct 12, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Nick GebruersEric van Breda
Sep 7, 2018·Breast Cancer Research and Treatment·Ian S Fentiman
Oct 28, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Tessa De VriezeNele Devoogdt
Aug 28, 2020·Current Opinion in Oncology·Chiara CortiGiuseppe Curigliano
Nov 26, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Tessa De VriezeNele Devoogdt
Oct 30, 2020·Breast Cancer : Targets and Therapy·Ayorinde AdehinOluseye Oladotun Bolaji
Apr 5, 2021·Lancet·Sibylle LoiblGiuseppe Curigliano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.